ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.738,17
-0,13%
Dow Jones
42.313,00
0,33%
Euro vs US Dollar
1,11658
-0,09%
Bitcoin
65.787,02
0,93%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. NeuroBo Pharmaceuticals Inc (NRBO)

  7. NeuroBo Pharmaceuticals Inc (NRBO) News

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NRBO
DatumZeitQuelleÜberschriftSymbolFirma
20/09/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
20/09/202422h15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
19/09/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/09/202414h01PR Newswire (US)NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
21/08/202422h02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202423h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/08/202414h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/08/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/07/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/07/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01NASDAQ:NRBONeuroBo Pharmaceuticals Inc
25/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRBONeuroBo Pharmaceuticals Inc
24/07/202423h11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/07/202414h21Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NRBONeuroBo Pharmaceuticals Inc
16/07/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
10/07/202417h11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
26/06/202415h06PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
25/06/202423h08PR Newswire (US)NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
24/06/202414h01PR Newswire (US)NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
22/06/202414h01PR Newswire (US)NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
08/06/202401h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/06/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
22/05/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
22/05/202414h01PR Newswire (US)NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRBO

Kürzlich von Ihnen besucht

NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
TG
ALV
Allianz
TG
TUI1
Tui
CCOM
US30
US 30
NASDAQ
TSLA
Tesla
USOTC
ADDYY
Adidas (QX)
COIN
ADAUSD
Cardano
CCOM
US100
US Tech 100
FX
EURJPY
Euro vs Yen
COIN
AVAXUSD
Avalanche
TG
LHA
Deutsche Lufthansa
FX
EURGBP
Euro vs Sterling
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten